This drug entry is astuband has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Generic Name
- RUTI® Vaccine
- DrugBank Accession Number
- DB15853
- Background
-
The RUTI® Vaccine contains fragmented, purified and liposomed heat-inactivated Mycobacterium tuberculosis bacilli. The vaccine has demonstrated a reasonable safety profile and potent stimulation of the immune response against tuberculosis. Much like the BCG vaccine, the RUTI® vaccine is also being tested as a prophylactic for SARS-CoV2. Sponsored by Fundació Institut Germans Trias i Pujol, the RUTI® Vaccine is being tested for prevention of COVID-19 infection in a controlled trial with 315 healthcare worker participants (NCT04453488).
- Type
- Biotech
- Groups
- Investigational
- Biologic Classification
-
Vaccines
Inactivated - Synonyms
- Not Available
- External IDs
-
- RUTI® Vaccine
Ph值armacology
- Indication
-
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning models
与evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets. - Contraindications & Blackbox Warnings
-
Avoid life-threatening adverse drug eventsImprove clinical decision support with information oncontraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events & improve clinical decision support. - Ph值armacodynamics
-
Not Available
- Mechanism of action
- Not Available
- Absorption
-
Not Available
- Volume of distribution
-
Not Available
- Protein binding
-
Not Available
- Metabolism
- Not Available
- Route of elimination
-
Not Available
- Half-life
-
Not Available
- Clearance
-
Not Available
- Adverse Effects
-
Improve decision support & research outcomesWith structured adverse effects data, including:blackbox warnings, adverse reactions, warning & precautions, & incidence rates.Improve decision support & research outcomes with our structured adverse effects data. - Toxicity
-
Not Available
- Pathways
- Not Available
- Ph值armacogenomic Effects/ADRsBrowse all" title="" id="snp-actions-info" class="drug-info-popup" href="javascript:void(0);">
- Not Available
Interactions
- Drug InteractionsLearn More" title="" id="structured-interactions-info" class="drug-info-popup" href="javascript:void(0);">
-
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Categories
- Drug Categories
-
Not Available
- Classification
- Not classified
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- Not Available
- CAS number
- Not Available
References
- 一般引用
-
- Vilaplana C, Montane E, Pinto S, Barriocanal AM, Domenech G, Torres F, Cardona PJ, Costa J: Double-blind, randomized, placebo-controlled Phase I Clinical Trial of the therapeutical antituberculous vaccine RUTI. Vaccine. 2010 Jan 22;28(4):1106-16. doi: 10.1016/j.vaccine.2009.09.134. Epub 2009 Oct 22. [Article]
- Nell AS, D'lom E, Bouic P, Sabate M, Bosser R, Picas J, Amat M, Churchyard G, Cardona PJ: Safety, tolerability, and immunogenicity of the novel antituberculous vaccine RUTI: randomized, placebo-controlled phase II clinical trial in patients with latent tuberculosis infection. PLoS One. 2014 Feb 26;9(2):e89612. doi: 10.1371/journal.pone.0089612. eCollection 2014. [Article]
- Prabowo SA, Painter H, Zelmer A, Smith SG, Seifert K, Amat M, Cardona PJ, Fletcher HA: RUTI Vaccination Enhances Inhibition of Mycobacterial Growth ex vivo and Induces a Shift of Monocyte Phenotype in Mice. Front Immunol. 2019 Apr 30;10:894. doi: 10.3389/fimmu.2019.00894. eCollection 2019. [Article]
- Trial Announced [Link]
- News for Covid-19 [Link]
- External Links
- Not Available
Clinical Trials
- Clinical TrialsLearn More" title="" id="clinical-trials-info" class="drug-info-popup" href="javascript:void(0);">
-
Ph值ase Status Purpose Conditions Count 3 Unknown Status Prevention Coronavirus Disease 2019 (COVID‑19) 1 2 Completed Prevention Coronavirus Disease 2019 (COVID‑19) 1 2 Recruiting Treatment Pulmonary Tuberculosis (TB) 1 2 Terminated Treatment Multidrug Resistant Tuberculosis 1 2 Withdrawn Treatment Tuberculosis (TB) 1 2, 3 Withdrawn Treatment Coronavirus Disease 2019 (COVID‑19) 1
Ph值armacoeconomics
- Manufacturers
-
Not Available
- Packagers
-
Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
Drug created at September 17, 2020 20:47 / Updated at September 18, 2020 08:47